Get the Stockscreener App
7.18
3.76%
0.26
Neuphoria Therapeutics Inc stock is traded at $7.18, with a volume of 9,275.
It is up +3.76% in the last 24 hours and down -6.75% over the past month.
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
See More
Previous Close:
$6.92
Open:
$7.02
24h Volume:
9,275
Relative Volume:
0.29
Market Cap:
$13.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.36%
1M Performance:
-6.75%
6M Performance:
+47.13%
1Y Performance:
+0.00%
1-Day Range:
$7.00
$7.1879
1-Week Range:
$6.815
$8.19
52-Week Range:
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
7.18 | 14.64M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Volatility clustering patterns for Neuphoria Therapeutics Inc.Gap Down & Fast Moving Stock Watchlists - Newser
Sentiment analysis tools applied to Neuphoria Therapeutics Inc.July 2025 Volume & High Accuracy Swing Entry Alerts - Newser
Chart based exit strategy for Neuphoria Therapeutics Inc.Quarterly Portfolio Report & Long-Term Investment Growth Plans - Newser
Exit strategy if you’re trapped in Neuphoria Therapeutics Inc.July 2025 Breakouts & Capital Protection Trading Alerts - Newser
Is Neuphoria Therapeutics Inc. reversing from oversold territoryFed Meeting & Low Drawdown Trading Strategies - Newser
Is it too late to sell Neuphoria Therapeutics Inc.2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
Is Neuphoria Therapeutics Inc. stock entering bullish territoryNew Guidance & Free Accurate Trade Setup Notifications - Newser
How to build a dashboard for Neuphoria Therapeutics Inc. stockPortfolio Gains Summary & Target Return Focused Stock Picks - Newser
Can momentum traders help lift Neuphoria Therapeutics Inc.Risk Management & Daily Profit Maximizing Tips - Newser
Statistical indicators supporting Neuphoria Therapeutics Inc.’s strengthJuly 2025 News Drivers & Intraday High Probability Setup Alerts - Newser
What to expect from Neuphoria Therapeutics Inc. in the next 30 daysPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
Identifying reversal signals in Neuphoria Therapeutics Inc.2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - Newser
Will breakout in Neuphoria Therapeutics Inc. lead to full recoveryProfit Target & Free High Return Stock Watch Alerts - Newser
Neuphoria Therapeutics Inc. stock trend outlook and recovery path2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Analyzing Neuphoria Therapeutics Inc. with multi timeframe charts2025 Major Catalysts & Technical Entry and Exit Tips - Newser
What momentum shifts mean for Neuphoria Therapeutics Inc.CPI Data & AI Powered Buy and Sell Recommendations - Newser
How hedge fund analytics apply to Neuphoria Therapeutics Inc. stock2025 Growth vs Value & Fast Exit and Entry Strategy Plans - Newser
Neuphoria Therapeutics Inc. stock momentum explained2025 Support & Resistance & Momentum Based Trading Signals - Newser
Forecasting Neuphoria Therapeutics Inc. price range with options dataPortfolio Risk Summary & Expert Curated Trade Setup Alerts - Newser
Evaluating Neuphoria Therapeutics Inc. with trendline analysisPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Will Neuphoria Therapeutics Inc. continue its uptrend2025 Performance Recap & Real-Time Chart Breakout Alerts - Newser
How to integrate Neuphoria Therapeutics Inc. into portfolio analysis tools2025 Support & Resistance & High Yield Stock Recommendations - Newser
Published on: 2025-08-17 00:10:08 - Newser
Why Neuphoria Therapeutics Inc. stock attracts strong analyst attentionEarnings Recap Summary & Daily Entry Point Alerts - Newser
Analyzing drawdowns of Neuphoria Therapeutics Inc. with statistical toolsPortfolio Value Report & Free Accurate Trade Setup Notifications - Newser
Live market analysis of Neuphoria Therapeutics Inc.Chart Signals & Fast Exit and Entry Trade Guides - Newser
Is Neuphoria Therapeutics Inc.’s ROIC above industry averageJuly 2025 Review & Stepwise Entry/Exit Trade Alerts - 선데이타임즈
Combining machine learning predictions for Neuphoria Therapeutics Inc.July 2025 Setups & Low Risk Profit Maximizing Plans - Newser
What MACD and RSI say about Neuphoria Therapeutics Inc.Inflation Watch & Target Return Focused Picks - Newser
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
There is no financial data for Neuphoria Therapeutics Inc (NEUP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):